Skip to content

Active Surveillance for Limited GGNs

Active Surveillance for Patients with Limited Ground-glass Nodules in China: a Prospective Multi-center Single-arm Trial (ECTOP-1028)

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06394037
Enrollment
387
Registered
2024-05-01
Start date
2025-05-01
Completion date
2038-05-01
Last updated
2025-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Active Surveillance, Lung Ground-glass Opacities

Brief summary

This study is a single-arm, multi-center, phase III trial conducted under the Eastern Cooperative Thoracic Oncoloy Project (ECTOP) . The primary objective of the study is to assess the 5-year overall survival of patients with one or two ground-glass opacities by employing an active surveillance approach rather than immediate surgical resection.

Detailed description

The trial aims to confirm the hypotheses that delaying surgery until GGO nodules exhibit progression or meet certain criteria offers a prognosis equivalent to those undergoing immediate surgical resection, potentially allowing many of these patients to avoid surgery altogether.

Interventions

PROCEDUREActive surveillance

Conduct thoracic computed tomography scans every 12 months. If progression occurs, the treamtent approach would involve surgery.

Sponsors

Fudan University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

Patients eligible for enrollment in the study are required to meet all the following criteria. 1. Demonstrates the following on thin-section computed tomography (TSCT) scan: 1. Presence of one or two GGNs (bilateral lesions are permitted). 2. All lesions have remained stable without regression or enlargement for at least 3 months. 3. The dominant lesion (the lesion with the largest maximum tumor diameter) has a maximum tumor diameter ≥0.6cm and ≤2cm. 4. CTR ≤0.25 in lesions. 5. No lymph node with a diameter \>1cm in the mediastinal view. 6. Not adjacent to the pleura in dominant lesion and no sign of pleural retraction in any lesions. 2. Has not previously undergo any anti-tumor drug or radiation therapy for the lung lesions. 3. Aged 18-75 years. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 5. Written informed consent. Patients will be excluded if they meet any of the following criteria. 1. History of any prior malignancies within the past 5 years. 2. History of lung surgery. 3. History of interstitial pneumonia, pulmonary fibrosis or other severe pulmonary diseases. 4. Presence of severe or uncontrolled diseases that may possibly reduce the 10-year life expectancy.

Design outcomes

Primary

MeasureTime frameDescription
5-year overall survival5 yearsThe event is defined as the death due to any causes.

Secondary

MeasureTime frameDescription
10-year overall survival10 yearsThe event is defined as the death due to any causes.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026